#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Renal cell carcinoma Craniopharyngioma Leber's congenital amaurosis Breast cancer Mycobacterium abscessus infection Pyruvate kinase deficiency anaemia ABO haemolytic disease of newborn Anaplastic large cell lymphoma T- and null-cell types Vernal keratoconjunctivitis Conjunctivitis allergic Cerebral amyloid angiopathy Malformation venous Epstein-Barr virus associated lymphoproliferative disorder Infantile apnoea Sickle cell disease More trials…

    Learn about Rare Diseases

    Prolymphocytic leukaemia – Trials in Disease Progressive multifocal leukoencephalopathy – Diagnostics Prader-Willi syndrome – Life with Disease Inclusion body myositis – Trials in Disease Breast angiosarcoma – Basic Information Waldenstrom’s macroglobulinaemia refractory – Treatment Short-bowel syndrome – Trials in Disease Friedreich’s ataxia – Life with Disease Cystic fibrosis – Trials in Disease Adrenogenital syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Epacadostat Lerodalcibep Rbd4059 Amb-05X Zamtocabtagene Autoleucel Izorlisib Mesilate CHLOROQUINE PHOSPHATE Tabelecleucel TTX-381 Nilutamide Nipocalimab Lavender Oil Inaxaplin Ecoo25B Ebastine Ezabenlimab Defactinib Golodirsen Nms-03305293 Clemastine Fumarate More therapies…

    Learn about Your Condition

    Hypervolaemia Cardiac failure acute Apathy Cardiac failure chronic Usher's syndrome Small cell carcinoma Oesophageal carcinoma Pancreatic carcinoma stage IV Alport's syndrome Immune system disorder Nephrotic syndrome Osteochondrodysplasia Breast conserving surgery Small cell lung cancer Coeliac disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Pegfilgrastim
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Ireland +5

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Cyclophosphamide
    • Docetaxel
    France Germany Italy The Netherlands Spain

  • A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • AB521
    • Placebo
    • Cabozantinib
    Czechia France Germany Italy The Netherlands Poland +2

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Xaluritamig
    Austria Belgium France Germany Greece Italy +3

  • Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    France

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France

  • A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • ABIRATERONE DECANOATE
    • Abiraterone Acetate
    • Prednisolone
    France Germany Italy Poland Spain

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Pegfilgrastim
    • Capecitabine
    • Carboplatin
    Austria France Germany Greece Italy Poland +4

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    • Breast cancer metastatic
    • Non-small cell lung cancer
    Investigated Drugs:
    • 177LU-FAP-2286
    • Calcium Folinate
    • Fluorouracil
    Belgium France Italy Spain
Previous Page
1 2 3 4 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!